156 related articles for article (PubMed ID: 22764174)
1. Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials.
Sun Y; Li M; Gilbert PB
Biostatistics; 2013 Jan; 14(1):60-74. PubMed ID: 22764174
[TBL] [Abstract][Full Text] [Related]
2. PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS.
Sun Y; Gilbert PB; McKeague IW
Ann Stat; 2009 Feb; 37(1):394-426. PubMed ID: 19838313
[TBL] [Abstract][Full Text] [Related]
3. Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy.
Juraska M; Gilbert PB
Biometrics; 2013 Jun; 69(2):328-37. PubMed ID: 23421613
[TBL] [Abstract][Full Text] [Related]
4. Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark.
Sun Y; Li M; Gilbert PB
Comput Stat Data Anal; 2016 Jan; 93():348-358. PubMed ID: 26461462
[TBL] [Abstract][Full Text] [Related]
5. Hypothesis tests for stratified mark-specific proportional hazards models with missing covariates, with application to HIV vaccine efficacy trials.
Sun Y; Qi L; Yang G; Gilbert PB
Biom J; 2018 May; 60(3):516-536. PubMed ID: 29488249
[TBL] [Abstract][Full Text] [Related]
6. Mark-specific additive hazards regression with continuous marks.
Han D; Sun L; Sun Y; Qi L
Lifetime Data Anal; 2017 Jul; 23(3):467-494. PubMed ID: 27170333
[TBL] [Abstract][Full Text] [Related]
7. Mark-specific hazard ratio model with missing multivariate marks.
Juraska M; Gilbert PB
Lifetime Data Anal; 2016 Oct; 22(4):606-25. PubMed ID: 26511033
[TBL] [Abstract][Full Text] [Related]
8. The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.
Gilbert PB; McKeague IW; Sun Y
Biostatistics; 2008 Apr; 9(2):263-76. PubMed ID: 17704528
[TBL] [Abstract][Full Text] [Related]
9. Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection.
Gilbert PB
Stat Med; 2000 Nov; 19(22):3065-86. PubMed ID: 11113943
[TBL] [Abstract][Full Text] [Related]
10. Variable selection for a mark-specific additive hazards model using the adaptive LASSO.
Han D; Qu L; Sun L; Sun Y
Stat Methods Med Res; 2021 Sep; 30(9):2017-2031. PubMed ID: 34266342
[TBL] [Abstract][Full Text] [Related]
11. Estimation of Stratified Mark-Specific Proportional Hazards Models with Missing Marks.
Sun Y; Gilbert PB
Scand Stat Theory Appl; 2012 Mar; 39(1):34-52. PubMed ID: 23519918
[TBL] [Abstract][Full Text] [Related]
12. Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to HIV vaccine efficacy trials.
Gilbert PB; Sun Y
J R Stat Soc Ser C Appl Stat; 2015 Jan; 64(1):49-73. PubMed ID: 25641990
[TBL] [Abstract][Full Text] [Related]
13. Estimation of Stratified Mark-Specific Proportional Hazards Models under Two-Phase Sampling with Application to HIV Vaccine Efficacy Trials.
Yang G; Sun Y; Qi L; Gilbert PB
Stat Biosci; 2017 Jun; 9(1):259-283. PubMed ID: 28781713
[TBL] [Abstract][Full Text] [Related]
14. Calibration weighted estimation of semiparametric transformation models for two-phase sampling.
Fong Y; Gilbert P
Stat Med; 2015 May; 34(10):1695-707. PubMed ID: 25648332
[TBL] [Abstract][Full Text] [Related]
15. Joint inferences on vaccine efficacy against infection and disease with application to the first HIV vaccine efficacy trial.
Cai T; Gilbert PB; Self SG
J Biopharm Stat; 2006; 16(4):517-38. PubMed ID: 16892911
[TBL] [Abstract][Full Text] [Related]
16. Incorporating founder virus information in vaccine field trials.
Follmann D; Huang CY
Biometrics; 2015 Jun; 71(2):386-96. PubMed ID: 25773491
[TBL] [Abstract][Full Text] [Related]
17. Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy.
Gilbert PB
Stat Med; 2001 Jan; 20(2):263-79. PubMed ID: 11169601
[TBL] [Abstract][Full Text] [Related]
18. Goodness-of-fit test for monotone proportional subdistribution hazards assumptions based on weighted residuals.
Boher JM; Filleron T; Giorgi R; Kramar A; Cook RJ
Stat Med; 2017 Jan; 36(2):362-377. PubMed ID: 27790725
[TBL] [Abstract][Full Text] [Related]
19. Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics.
Dai JY; Li SS; Gilbert PB
Biostatistics; 2014 Jan; 15(1):196-203. PubMed ID: 23813283
[TBL] [Abstract][Full Text] [Related]
20. Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials.
Li Z; Gilbert P; Nan B
Biometrics; 2008 Dec; 64(4):1247-55. PubMed ID: 19032178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]